Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth

Rhea-AI Summary

Trinity Biotech (Nasdaq: TRIB) on October 27, 2025 welcomed an indicated proposal from its largest investor and primary lender, Perceptive Advisors, to convert a portion of outstanding debt and other obligations into equity.

The company said the proposed equitization, if implemented, could strengthen the balance sheet, enhance financial flexibility and support its growth objectives while the company engages in discussions with Perceptive and other stakeholders. The release also reiterates standard forward-looking statement cautions and lists risks that could affect outcomes.

DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that the Company welcomes the indicated intention of its largest investor and primary lender, Perceptive Advisors, to submit a proposal that, if implemented, would facilitate the conversion of a portion of the Company’s outstanding debt and other obligations into equity.

The Company believes this strategic initiative represents a constructive step toward strengthening its balance sheet and that an equitization program, if successfully executed, could enhance the Company’s financial flexibility and support its ambitious growth objectives.

Perceptive Advisors is a leading life sciences investment firm that has continued to be a supportive and constructive investment partner to the Company through its recent transformation journey.

The Company looks forward to engaging in discussions that are mutually beneficial and aligned with the interests of all of its stakeholders, including shareholders.

Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, the impact of the U.S. government shut-down, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

About Trinity Biotech

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company’s website: www.trinitybiotech.com.

About Perceptive Advisors

Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment management firm with approximately $8 billion in assets. Perceptive Advisors is focused on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare. For more information visit www.perceptivelife.com.

Contact:	Trinity Biotech plc	RedChip Companies Inc.
	Susan O’Connor	Dave Gentry, CEO
	(353)-1-2769800	(1)-407-644-4256
		(1)-800-RED-CHIP (733-2447)
		TRIB@redchip.com

FAQ

What did Trinity Biotech (TRIB) announce on October 27, 2025 about debt-to-equity conversion?

Trinity Biotech said Perceptive Advisors indicated a proposal to convert a portion of the company’s outstanding debt and other obligations into equity.

How could Perceptive Advisors’ proposed conversion affect TRIB shareholders?

The company said an executed equitization could strengthen the balance sheet and enhance financial flexibility; specific shareholder effects were not disclosed.

Has Trinity Biotech (TRIB) finalized terms or amounts for the proposed debt-to-equity conversion?

No; Trinity Biotech described an indicated proposal and said discussions are expected; no binding terms, amounts or timelines were provided.

Will the proposed Perceptive Advisors conversion immediately change TRIB’s capital structure?

Not yet; the announcement indicates an intention to submit a proposal but does not state that any conversion has been implemented.

Does the TRIB announcement mention risks tied to the proposed equitization?

Yes; the release reiterates forward-looking statement cautions and lists risks that could affect the company’s financial position and operations.

Where can investors find updates on Trinity Biotech (TRIB) regarding this proposal?

Investors should monitor Trinity Biotech’s subsequent SEC filings and company announcements for any definitive agreements or material terms.